{"nctId":"NCT01968460","briefTitle":"Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease","startDateStruct":{"date":"2013-12"},"conditions":["Parkinson's Disease"],"count":149,"armGroups":[{"label":"P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),","type":"EXPERIMENTAL","interventionNames":["Drug: P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),"]},{"label":"P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),","type":"EXPERIMENTAL","interventionNames":["Drug: P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject is male or female ≥35 years of age to ≤75 years of age at the time of enrollment.\n* Subject has idiopathic Parkinson's disease consistent with the UK Brain Bank Criteria; must have bradykinesia with sequence effect and rest tremor or prominent motor asymmetry.\n* Subject with disease duration no longer than 3 years and 0 months.\n* Subject has a Hoehn \\& Yahr (H\\&Y) stage score of \\< 3.\n* Subject has a MMSE score ≥ 26\n\nExclusion Criteria:\n\n* Subject has an atypical parkinsonian syndrome or secondary parkinsonism (e.g., due to drugs, metabolic neurogenetic disorders, encephalitis, cerebrovascular disease or degenerative disease).\n* Subject has a history of psychosis or hallucinations within the previous 12 months.\n* Subject who is taking anticholinergic drugs.\n* Subject has previous exposure to levodopa or a dopamine agonist for longer than 4 weeks; if previous exposure was less than 4 weeks then it must not be within 2 months prior to the baseline visit.\n* Subject has previous exposure to a MAO-B inhibitor for longer than 4 weeks; if previous exposure was less than 4 weeks then it must not be within 3 months prior to the baseline visit.\n* Subject who is taking MAO inhibitors, potent CYP1A2 inhibitors, e,g, Ciprofloxacin, Dextromethorphan or antitussive agent, analgesic agents such as tramadol, meperidine, methadone and propoxyphene, strong 3A4 inducers, e.g., St. John's Wort or cyclobenzaprine (tricyclic muscle relaxant), dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide. Probenecid, cimetidine, ranitidine, diltiazem, verapamil and quinidine.","healthyVolunteers":false,"sex":"ALL","minimumAge":"35 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Total UPDRS I, II, III Scores","description":"Change from baseline to final visit (week 12) in total UPDRS score (defined as sum of parts I, II and III, scores (0-176). UPDRS- Unified Parkinson's Disease Rating Scale, minimum value is 0 points and maximum value is 176.\n\nHigh score mean worse outcome.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.97","spread":"0.94"},{"groupId":"OG001","value":"-5.15","spread":"0.9"},{"groupId":"OG002","value":"-1.31","spread":"0.88"}]}]}]},{"type":"SECONDARY","title":"UPDRS ADL (Part II)","description":"Change from baseline in individual UPDRS ADL (part II). Activity of daily Life UPDRS part II minimum is 0 point and max is 52 point (worse outcome)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.49","spread":"0.37"},{"groupId":"OG001","value":"-1.06","spread":"0.36"},{"groupId":"OG002","value":"0.36","spread":"0.39"}]}]}]},{"type":"SECONDARY","title":"CGI-S","description":"Change from baseline in individual Clinical Global Impression - Severity. Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness (Parkinson's Disease) at the time of assessment relative to the clinician's past experience with patients who have the same diagnosis as one of the following:. 1 is normal and 7 is the most extremely ill patients. A subject defined as a treatment responder when the improvement from baseline to the Week12 / Last Observed Value (LOV) was of at least 1 point or more.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"UPDRS Motor (Part III)","description":"Change from baseline in individual UPDRS motor (part III). UPDRS- Unified Parkinson's Disease Rating Scale, part III motor . min is 0 and Max is 108 (Worse outcome)","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.43","spread":"0.74"},{"groupId":"OG001","value":"-3.95","spread":"0.7"},{"groupId":"OG002","value":"-1.62","spread":"0.69"}]}]}]},{"type":"SECONDARY","title":"PDQ39","description":"Change from baseline in individual Parkinson's Disease Questionnaire - 39. Score 0-100 where 0 is indicative of no problem at all and 100 is the maximum level of problem.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.01","spread":"0.89"},{"groupId":"OG001","value":"-2.19","spread":"0.88"},{"groupId":"OG002","value":"0.26","spread":"0.88"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":49},"commonTop":["NAUSEA","SOMNOLENCE","DIZZINESS","tremor","nasopharyngitis"]}}}